Regen BioPharma Inc (RGBP)

Name: Regen BioPharma Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$59.1K

Net Income

-$968K

Operating Margin

-933.9%

Free Cash Flow

-$384K

Debt / Assets

2,387.2%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Regen BioPharma Inc (RGBP).
Income Statement (Quarterly)	2025-12-31	2024-12-31	2024-09-30	2024-06-30
Revenue	59,065	59,065	59,366	59,065
Cost of Revenue	0	59,065	59,366	0
Gross Profit	59,065	0	59,366	59,065
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	385,689	131,602	112,212	134,531
Operating Expenses	610,689	131,602	145,736	167,031
Operating Income	-551,624	-72,537	-86,370	-107,966
Interest Expense	35,403	37,991	181,516	21,893
Income Before Tax	-967,853	-460,815	-265,000	-130,120
Income Tax Expense	0	0	0	0
Net Income	-967,853	-460,815	-167,000	-117,108
Per Share
EPS	-0.01	-0.03	-0.03	-0.03
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Regen BioPharma Inc (RGBP).
Income Statement (Annual)	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30
Revenue	236,561	236,560	236,560	235,517	171,194
Cost of Revenue	0	77,215	60,000	50,000	0
Gross Profit	236,561	159,345	236,560	185,517	0
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	473,376	423,849	711,212	299,734	335,260
Operating Expenses	575,101	577,534	923,510	575,122	371,964
Operating Income	-338,540	-417,000	-687,000	-339,605	-200,771
Interest Expense	210,434	246,943	309,448	209,787	367,028
Income Before Tax	-1,274,502	-668,000	1,157,000	2,443,532	-6,765,232
Income Tax Expense	0	0	0	-3,046,335	0
Net Income	-1,274,502	-668,000	1,024,000	5,489,867	-6,765,233
Per Share
EPS	-0.05	-0.08	0.14	1.75	0.00
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Regen BioPharma Inc (RGBP).
Balance Sheet (Quarterly)	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Assets
Cash and Cash Equivalents	716	716	121,037	51,204
Short Term Investments	0	0	0	0
Net Receivables	204,873	94,873	0	254,273
Inventory	0	0	0	0
Total Current Assets	274,628	159,878	131,037	336,422
Property Plant Equipment	0	0	0	0
Goodwill and Intangibles	0	0	0	0
Total Assets	274,628	177,611	353,617	559,002
Liabilities
Account Payables	29,669	29,669	29,674	28,799
Short Term Debt	793,699	814,699	606,590	1,274,050
Total Current Liabilities	6,555,811	5,371,640	5,308,003	8,595,061
Long Term Debt	0	0	149,614	0
Total Liabilities	6,555,811	5,371,640	5,457,616	8,595,061
Shareholders Equity
Retained Earnings	-21,691,620	-20,616,114	-19,748,863	-20,905,369
Total Shareholders Equity	-6,281,183	-5,194,029	-5,104,000	-8,036,059

Balance sheet annual history for Regen BioPharma Inc (RGBP).
Balance Sheet (Annual)	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30
Assets
Cash and Cash Equivalents	716	716	121,037	51,204	727,162
Short Term Investments	0	0	0	0	0
Net Receivables	204,873	94,873	0	254,273	218,818
Inventory	0	0	0	0	0
Total Current Assets	274,628	159,878	131,037	336,422	994,124
Property Plant Equipment	0	0	0	0	0
Goodwill and Intangibles	0	0	0	0	0
Total Assets	274,628	177,611	353,617	559,002	1,212,099
Liabilities
Account Payables	29,669	29,669	29,674	28,799	91,498
Short Term Debt	793,699	814,699	606,590	1,274,050	3,582,990
Total Current Liabilities	6,555,811	5,371,640	5,308,003	8,595,061	14,697,976
Long Term Debt	0	0	149,614	0	0
Total Liabilities	6,555,811	5,371,640	5,457,616	8,595,061	14,697,976
Shareholders Equity
Retained Earnings	-21,691,620	-20,616,114	-19,748,863	-20,905,369	-23,348,900
Total Shareholders Equity	-6,281,183	-5,194,029	-5,104,000	-8,036,059	-13,485,877

Cash flow quarterly history for Regen BioPharma Inc (RGBP).
Cash Flow Statement (Quarterly)	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Operating Activities
Net Income	-1,274,502	-867,252	1,156,507	2,443,531
Depreciation & Amortization	52,148	28,998	864	71,067
Stock Based Compensation	0	5,876	348,372	45,500
Change in Working Capital	35,135	0	-1,928,511	-3,137,415
Operating Cash Flow	-383,591	-693,141	-173,917	-606,921
Investing Activities
Capital Expenditure	0	0	-3	0
Investments	0	0	-3	0
Investing Cash Flow	0	0	0	25,000
Financing Activities
Debt Repayment	344,230	0	-243,750	-94,535
Common Stock Issued/Repurchased	58,200	145,500	250,000	45,500
Dividends Paid	0	0	0	0
Financing Cash Flow	452,430	572,819	243,750	-94,036
Summary
Free Cash Flow	-383,591	-693,141	-173,920	-606,921
Net Change in Cash	68,839	-120,322	69,833	-675,958

Cash flow annual history for Regen BioPharma Inc (RGBP).
Cash Flow Statement (Annual)	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30
Operating Activities
Net Income	-1,274,502	-867,252	1,156,507	2,443,531	-6,765,233
Depreciation & Amortization	52,148	28,998	864	71,067	0
Stock Based Compensation	0	5,876	348,372	45,500	1
Change in Working Capital	35,135	0	-1,928,511	-3,137,415	4,450,461
Operating Cash Flow	-383,591	-693,141	-173,917	-606,921	-1,130,938
Investing Activities
Capital Expenditure	0	0	-3	0	0
Investments	0	0	-3	0	0
Investing Cash Flow	0	0	0	25,000	495,000
Financing Activities
Debt Repayment	344,230	0	-243,750	-94,535	0
Common Stock Issued/Repurchased	58,200	145,500	250,000	45,500	0
Dividends Paid	0	0	0	0	0
Financing Cash Flow	452,430	572,819	243,750	-94,036	1,363,100
Summary
Free Cash Flow	-383,591	-693,141	-173,920	-606,921	-1,130,938
Net Change in Cash	68,839	-120,322	69,833	-675,958	1,363,100